John F. Reilly
About John F. Reilly
Current Role as Chief Scientific Officer at Nereid Therapeutics
John F. Reilly currently serves as the Chief Scientific Officer at ATP Portfolio Company Nereid Therapeutics. In his role, he is responsible for overseeing the scientific strategy and research initiatives of the company, ensuring alignment with their mission and goals. His leadership is integral in driving forward the company's biotechnological and therapeutic advancements.
Educational Background in Molecular Biology and Neuroscience
John F. Reilly earned a Bachelor of Arts in molecular and cell biology from the University of California, Berkeley. He further pursued his academic interests by obtaining a PhD in neuroscience from the University of California, Davis. He completed postdoctoral training at the prestigious Scripps Research Institute, which equipped him with advanced research skills and comprehensive knowledge in his field.
Past Experience at Goldfinch Bio and Catabasis Pharmaceuticals
John F. Reilly has held significant roles in the biotechnology and pharmaceuticals sectors. He served as senior vice president of Biology at Goldfinch Bio, where he likely guided biological research and development. Prior to this, he was the executive director of Biology at Catabasis Pharmaceuticals, contributing to the company's drug discovery and development processes.
Leadership at Novartis Institutes for BioMedical Research
John F. Reilly was formerly the global head of Applied Human Genetics & Genomics at Novartis Institutes for BioMedical Research. In this position, he led initiatives focused on the practical application of human genetics and genomics to develop novel therapies. His work likely had significant impact on the company's research and development pipeline.
Directorship at Merck Research Laboratories
While at Merck Research Laboratories, John F. Reilly directed Molecular Biomarkers, placing emphasis on anti-PD-1 biomarker efforts. His role would have involved identifying and validating biomarkers critical for the effectiveness and safety of therapeutic agents, particularly in immuno-oncology.